identified MUC1 as a key regulatory factor in the disease’s development, primarily through upregulating EGFR expression and activating the AKT signaling pathway to promote tumor cell proliferation, while also highlighting Taxol’s significant therapeutic potential in targeting ovarian cancers with abnormally high MUC1 expression (40). Here, AKT1 is linked to neoplasm.